Introduction
============

Despite advances in vitreoretinal microsurgery techniques over the years, epiretinal gliosis, such as idiopathic epiretinal membrane (iERM, also referred to as macular pucker), is a potentially sight-threatening vitreoretinal disorder, with aging being the principal nonmodifiable risk factor.[@b1-opth-10-921],[@b2-opth-10-921] Epidemiological studies have reported a prevalence of 1.02%--28.9% among different ethnic groups for iERM.[@b3-opth-10-921],[@b4-opth-10-921] Epiretinal gliosis on the macular surface ultimately leads to the formation of contractile tractional fibrocellular membranes, the development of severe retinal surface wrinkling, macular vascular distortion, and the breakdown of the blood--retinal barrier at the retinal pigment epithelial level. Limited understanding of the pathophysiology behind this vision-threatening vitreoretinal interface disease is hindering the development of nonsurgical treatment modalities.

iERM involves inflammation, immune response, for example, classical and alternative pathway of complement activation, proteolysis, and cytoskeleton remodeling.[@b5-opth-10-921]--[@b7-opth-10-921] Histologically, epiretinal membrane (ERM) is composed of multiple retinal and extraretinal cell types and extracellular matrix (ECM) proteins. Most internal limiting membrane (ILM) specimens removed from iERMs contain activated cells of glial origin (Müller cells, astrocytes, and microglia), hyalocytes, macrophages, fibroblasts, myofibroblasts, and retinal pigment epithelial cells, as well as ECM components, including newly formed collagens.[@b8-opth-10-921],[@b9-opth-10-921] Activated astro- and microglial cells have been also implicated as the key cell types involved in central nervous system (CNS) scar formation, and neuroinflammation and degeneration in the human retina.[@b10-opth-10-921]--[@b12-opth-10-921]

Fibrosis in the CNS and the vitreoretinal interface, an abnormal wound-healing process, is often related to ischemia (eg, vasoconstriction predisposed by smoking) and neuroinflammation. This involves upregulation of proinflammatory and profibrotic cytokines, adhesion molecules, and growth factors. Matrix metalloproteinases (MMPs), a group of zinc- and calcium-dependent proteinases, degrade components of the ECM, with MMP-2 and -9 being especially associated with the development of postoperative proliferative vitreoretinopathy (PVR).[@b13-opth-10-921] Transforming growth factor (TGF)-β, a multifunctional cytokine, is implicated in both barrier breakdown-induced permeability and fibroproliferation-induced contraction of PVR membranes.[@b14-opth-10-921],[@b15-opth-10-921] Moreover, vascular endothelial growth factor (VEGF) is linked to both vascular and avascular PVR membranes, and anti-VEGF therapies have shown a prophylactic effect against postoperative PVR formation.[@b16-opth-10-921],[@b17-opth-10-921] Angiopoietins (ANGPTs), potent regulators of endothelial cell--cell and cell--ECM interactions, were recently suggested as potential therapeutic targets in both neurotrauma and ischemia--reperfusion studies.[@b18-opth-10-921],[@b19-opth-10-921]

Statins, 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitors, were shown to reduce neuroinflammation and astrocyte activation in CNS injuries and enhance ganglion cell survival of ischemic rat retinas.[@b20-opth-10-921]--[@b22-opth-10-921] In eyes subjected to surgery for fibroproliferative vitreoretinal disease, microvascular- and neuroprotective actions of statins[@b23-opth-10-921]--[@b25-opth-10-921] might modulate integrity of the blood--retinal barrier, retinal wound healing, inflammation-related PVR, and photoreceptor survival.[@b26-opth-10-921],[@b27-opth-10-921]

In the present study, we investigated the intravitreal levels of vasoactive, proinflammatory, and fibrotic factors; the visual outcomes; and the probability of reoperations in a group of vitrectomized iERM patients on statin medication compared with patients without preoperative statin medication.

Materials and methods
=====================

Study design
------------

Patients were admitted for primary vitrectomy for management of iERM in the Unit of Vitreoretinal Surgery, Helsinki University Central Hospital, Helsinki, Finland. The study was conducted according to the tenets of the Declaration of Helsinki and was approved by the Institutional Review Board of Helsinki University Central Hospital. Signed informed consent was obtained from each participant before sampling. Confidentiality of the patient records was maintained when the clinical data were entered into a computer-based standardized data entry for analysis.

Patients and controls
---------------------

In this study, a total of 26 eyes of 25 patients who underwent primary vitrectomy for iERM between 2006 and 2008 were studied. Diagnosis of iERM was performed using optical coherence tomography. Data were further analyzed according to the use or nonuse of lipid-lowering statin therapy. Of the 26 cases, 12 were on statin treatment (nine on lipophilic simvastatin and three on lipophilic atorvastatin), and 14 were without any statins. Exclusion criteria were other retinal comorbidities such as diabetic retinopathy, inflammatory or retinal vascular disorder, or trauma. The clinical characteristics and concomitant interfering medication of the study patients are presented in [Tables 1](#t1-opth-10-921){ref-type="table"} and [2](#t2-opth-10-921){ref-type="table"}. Time of exposure to statin therapy was not documented in our study. The decision for statin therapy was taken by the general practitioner or internal medicine doctor.

Surgery
-------

Undiluted vitreous samples (up to 1,000 µL) were collected at the start of the standard three-port pars plana vitrectomy (20 or 23 Gauge, Accurus, Alcon Instruments, Inc, Fort Worth, TX, USA) without an infusion of artificial fluid. The samples were collected by manual aspiration into a syringe via the vitrectomy with the cutting function activated. Samples were transferred into sterile 1.5 mL Eppendorf tubes and immediately frozen at −70°C until laboratory analysis.

The surgical technique consisted of a standard three-port pars plana vitrectomy. If the vitreous was attached to the posterior retina, posterior vitreous detachment was induced by suction with the vitrectomy probe over the optic disc. To visualize and identify the posterior hyaloid, ERMs and the ILM, intravitreal vital dyes were used (chromovitrectomy). Diluted indocyanine green and/or MembraneBlue-Dual^®^ (D.O.R.C., Zuidland, the Netherlands) dye-assisted ERM ± ILM peeling was performed. Air--fluid exchange and flushing of the vitreous cavity with SF~6~ (sulfur hexafluoride) was performed in six eyes (23.1%), C~2~F~6~ (hexafluoroethane) in ten eyes (38.5%), and C~3~F~8~ (octafluoropropane) in one eye (3.8%). Nine (34.6%) eyes were filled with balanced salt solution.

Determination of biomarkers
---------------------------

Frozen vitreous humor samples were thawed and clarified by centrifugation at 13,000 rpm at room temperature for 5 minutes. A reference serum sample was used to calculate intra- and inter-assay variation. Standard curves were constructed by plotting the concentration and mean absorbance and the plates were analyzed using a Victor2 multilabel counter microplate reader (Wallac, Turku, Finland) at a wavelength of 450 nm. To calculate the concentration, the standards were fitted with a second-order polynomial equation.

For ANGPT-1 and -2 measurements in vitreous samples, we used solid-phase enzyme-linked immunosorbent assay (ELISA) kits (DANG10 and DANG20, R&D Systems, Minneapolis, MN, USA). Total TGF-β1 and VEGF levels in the vitreous were measured using Quantikine ELISA kits (DB100B and DVE00, respectively, R&D Systems). Latent forms of TGF-β1 were acid-activated before the assay according to the manufacturer's instructions. Erythropoietin (EPO) levels in the vitreous were determined by a Quantikine human EPO IVD ELISA (DEP00, R&D Systems).

Gelatin zymography was performed to evaluate total MMP-2 and -9 zymogens in the vitreous samples. To analyze the gelatinolytic proteins, aliquots of vitreous samples were subjected to gelatin zymography.[@b28-opth-10-921] Samples were dissolved in nonreducing Laemmli sample buffer and separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis using 10% polyacrylamide gels containing 1 mg/mL of gelatin. After electrophoresis, the gels were washed twice with 50 mM Tris--HCl, pH 7.6, containing 5 mM CaCl~2~, 1 µM ZnCl~2~, 2.5% Triton X-100 (v/v) for 15 minutes to remove sodium dodecyl sulfate, followed by a brief rinse in washing buffer without Triton X-100. The gels were then incubated at 37°C for 12--24 hours in 50 mM Tris--HCl buffer containing 5 mM CaCl~2~, 1 µM ZnCl~2~, 1% Triton X-100, 0.02% NaN~3~, pH 7.6. The gels were stained with Coomassie brilliant blue R250 followed by destaining with 10% acetic acid and 5% methanol. The zymogen gels were later scanned by an image scanner, and the areas of clear bands corresponding to MMP-2 and -9 activity were calculated using ImageJ software (v1.42q, NIH, Bethesda, MD, USA) on nonaltered original Tagged Image File Format files in the 8-bit dynamic range of signal intensities. The values are reported in arbitrary units (AU/mL).

Total protein measurement
-------------------------

Vitreous total protein concentrations (mg/mL) were measured to compare the undiluted vitreous catch between study groups using a bicinchonic acid protein assay kit (Pierce, Rockford, IL, USA) according to manufacturer's instructions. The intravitreal concentrations (ANGPT-1 and -2, VEGF, TGF-β1 \[pg/mL\]; EPO \[mIU/mL\]; or MMP-2 and -9 \[AU/mL\]) in eyes with iERM are given in relation to total protein concentration (mg/mL) in the vitreous sample.

Visual acuity testing
---------------------

Best-corrected visual acuity (BCVA) was measured in a single sitting under standardized low light conditions on a standard Snellen chart at an observation distance of 5 m. When the largest optotype could not be correctly recognized, the classification was very low VA on a semiquantitative scale such as counting fingers, hand motion, light perception, or no light perception. For statistical purposes, the Snellen values were transformed to the equivalent logarithm of the minimum angle of resolution (LogMAR) units. Very low VA measurements were converted as follows: counting fingers 1.9, hand motion 2.3, light perception 2.7, and no light perception 3.0 LogMAR.[@b29-opth-10-921]

Statistical analyses
--------------------

All data are presented as mean ± standard deviation, except for the absolute number and proportion for the nominal scale, and data were analyzed with SPSS 15.0 (SPSS Inc, Chicago, IL, USA). For two-group comparisons, qualitative data were analyzed using the two-factor *χ*^2^ test and continuous variables with the nonparametric Mann--Whitney *U*-test. Associations between variables were analyzed by Pearson's correlation. The need of revitrectomy was analyzed using the log-rank test. Death and the end of follow-up at 1 year were used as censoring events. *P*≤0.05 was considered statistically significant.

Results
=======

Baseline characteristics of the patients and vitrectomized eyes
---------------------------------------------------------------

The study groups were age- and sex-matched ([Table 1](#t1-opth-10-921){ref-type="table"}). All the subjects were of Caucasian origin. Interestingly, the majority of patients (58%--64%) were smokers in both study groups ([Table 1](#t1-opth-10-921){ref-type="table"}). The concomitant medication of the patients was similar between the groups, except for the fact that statin-treated patients had a higher probability of concomitant antidepressive medication (*P*=0.047, [Table 2](#t2-opth-10-921){ref-type="table"}).

Intravitreal protein levels
---------------------------

The intravitreal protein levels of EPO (*P*=0.003, [Table 3](#t3-opth-10-921){ref-type="table"}), TGF-β1 (*P*=0.035, [Table 3](#t3-opth-10-921){ref-type="table"}), and VEGF (*P*=0.006, [Table 3](#t3-opth-10-921){ref-type="table"}) were significantly lower in the statin-treated compared to nonstatin-treated patients with iERM. No difference emerged in the intravitreal ANGPT-1 and -2, or MMP-2 and -9 ([Table 3](#t3-opth-10-921){ref-type="table"}), or the plasma ANGPT-1 and -2 ([Table S1](#SD1-opth-10-921){ref-type="supplementary-material"}) protein levels between the study groups. Intravitreal EPO levels correlated significantly with those of intravitreal VEGF (*r*=0.892, *P*\<0.001) and TGF-β1 (*r*=0.695, *P*=0.001) levels (data not shown).

Postoperative outcomes
----------------------

Preoperatively, the mean BCVA of iERM eyes did not differ between statin- and nonstatin-treated study patients ([Table 4](#t4-opth-10-921){ref-type="table"}). Both the 1-month mean postoperative BCVA (*P*=0.053, [Table 4](#t4-opth-10-921){ref-type="table"}) and BCVA gain (*P*=0.118, [Table 4](#t4-opth-10-921){ref-type="table"}) did not significantly differ between the statin- compared to nonstatin-treated patients.

The number of eyes requiring revitrectomy during a 12-month follow-up was one of 12 in the statin group (due to rhegmatogenous retinal detachment \[RRD\]) and four of 14 in the nonstatin group (one due to RRD, one due to inferior PVR and RRD, and two due to recurrent ERM formation) (*P*=0.219, [Table 4](#t4-opth-10-921){ref-type="table"}). All secondary RRD cases occurred within 3--5 weeks of postprimary vitrectomy; they were reoperated and the retina was successfully reattached with gas or silicone oil. No endophthalmitis or prolonged hypotony was noted in the study eyes during the 12-month follow-up period.

Discussion
==========

The vitreoretinal interface disease iERM is a common age-associated sight-threatening disorder worldwide, with aging and the development of anomalous posterior vitreous detachment being the most important known risk factors.[@b2-opth-10-921] However, the underlying mechanisms of iERM formation remain unclear. Numerous studies have reported intravitreal biochemical factors associated with secondary puckers related to various posterior segment inflammatory diseases, venous occlusive diseases, diabetic retinopathy, RRD, retinopathy of prematurity, and vitreomacular traction syndromes in age-related macular degeneration with choroidal neovascularization or diabetic macular edema. However, reports of intravitreal biochemical factors in iERM formation are rather scarce.[@b8-opth-10-921] Thus, our finding that several intravitreal vasoactive, proinflammatory, and profibrotic biomarkers in iERM eyes seem to be regulated by statin could be of great clinical importance regarding future therapeutic approach.

The aging process in CNS is known to be associated with degenerative changes such as presence of oxidative, proteotoxic, and metabolic stresses.[@b30-opth-10-921] Glial cell responses seem to be similar in the brain and neural retina.[@b12-opth-10-921] Comorbidities, such as long-term smoking, systemic hypertension, hyperlipidemia, obesity, or ischemia with an inflammatory component, could also play a role in the development of these age-related eye diseases. Indeed, majority of our patients were current smokers. Lifetime exposure to smoking could be related to increased oxidative stress and free radical generation, both of which are known to serve as triggers for parainflammation, vascular dysfunction, and fibroproliferation at the CNS and retinal level.[@b31-opth-10-921],[@b32-opth-10-921] Depending on the genetic background, smoking may affect the reparative potential of eye fibroblasts and promote the activation of proinflammatory pathways.[@b33-opth-10-921] Modern brain imaging techniques, such as advanced magnetic resonance imaging or positron emission tomography, could be useful in correlating the results with fibrosis formation in iERM eyes to assess the extent of gliosis/fibrosis formation in the CNS.

Recent advances in proteomics, for example, have revealed that TGF-β1 is involved in iERM formation.[@b5-opth-10-921] TGF-β1 is known to be present at low levels in the adult CNS. Microglia, infiltrating monocytes/macrophages, platelets, and reactive astrocytes are the major sources of increased TGF-β1 during the early degenerative, remodeling, and healing phases in CNS disorders, such as ischemia and trauma.[@b34-opth-10-921],[@b35-opth-10-921] In the CNS, TGF-β1 can also act as a secondary mediator of injury and promote astrocyte activation together with interleukins, fibrinogen, nuclear factor kappa beta and signal transducer and activator of transcription 3 and stimulate them to transdifferentiate into contractile myofibroblasts.[@b36-opth-10-921],[@b37-opth-10-921] In our study, the fact that TGF-β1 levels in the eyes of patients with statin therapy were decreased compared with the levels in the nonstatin group could be due to differences in tissue remodeling mechanisms, perhaps reduced wound healing activity and epithelial-to-mesenchymal transition in eyes operated for iERM.[@b14-opth-10-921],[@b38-opth-10-921]

At best, surgical intervention is the choice of treatment only for a proportion of iERM cases. Furthermore, both existing intraocular fibrosis may cause irreversible tissue injury per se in the sensitive neuroretina and surgical removal of ERM may damage the nerve fiber layer, preventing the recovery of visual acuity even after a successful surgical procedure. Pharmacological interventions targeting CNS fibrosis would be of great importance. Statin use may modulate expression of proteins and cytokines associated with wound healing and survival.[@b39-opth-10-921] Furthermore, the role of angiogenic and antiangiogenic factors in iERM (eg, soluble VEGF receptor \[s-VEGFR-1\]) remains a topic for further research.[@b40-opth-10-921] In the future, the use of proteomics and genetics might enable better understanding of the pathophysiology of these complex age-related vitreoretinal interface disorders and improve nonsurgical treatment modalities for them.[@b41-opth-10-921]

The major strength of our study was its measurement of several intravitreal vasoactive, proinflammatory, and profibrotic biomarkers in patients admitted for primary vitrectomy for iERM. However, our study has several limitations. First, we did not excise the membranes for immunocytochemical or ultrastructural analysis, and the number of intravitreal specimens was limited in both groups. Second, our study design did not allow additional postoperative controls after 1 month, thus the follow-up does not provide the anatomical optical coherence tomography outcome results, and the documentation for need of reoperations is retrospective in nature. Our present preliminary findings, however, suggest that statin treatment might have a role in anti-inflammatory and antifibrotic process in the aging human eye.

Conclusion
==========

To conclude, the pathogenesis of fibrosis formation in the CNS and the aging eye is poorly understood, but can represent the end result of inflammation, apoptosis, proliferation, and abnormal wound healing. Currently, treatment strategies are limited, consisting of ophthalmic follow-up or microsurgery with pars plana vitrectomy with membrane peeling. Understanding of the regulation of fibrosis and modification of the fibrotic process is crucial to improve the surgical outcome of eyes with iERM. With the aging of the global population and the increasing life expectancy, the need for prevention and/or novel therapeutic approaches for fibrotic vitreoretinal interface diseases is growing.

Supplementary material
======================

###### 

Plasma protein concentrations in nonstatin- and statin-treated iERM patients

            Nonstatin (n=14)   Statin (n=12)     *P*-value
  --------- ------------------ ----------------- -----------
  ANGPT-1   3,112.5±2,018.1    3,888.4±2,517.2   0.456
  ANGPT-2   2,297.3±725.8      2,356.1±971.2     1.000

**Notes:** The plasma concentrations (ANGPT-1 and -2 \[pg/mL\]) in patients with iERM. Data presented as mean ± SD. For two group comparisons, a nonparametric Mann--Whitney *U*-test was used.

**Abbreviations:** ANGPT, angiopoietin; iERM, idiopathic epiretinal membrane; SD, standard deviation.
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###### 

Baseline characteristics

  Patient and ocular variables   Nonstatin (n=14)   Statin (n=12)   *P*-value
  ------------------------------ ------------------ --------------- -----------
  Age (years)                    69.5±7.0           69.9±4.6        0.667
  Male:female, n (%)             7:7 (50:50)        3:9 (25:75)     0.191
  BMI (kg/m^2^)                  29.9±12.0          27.5±3.9        0.979
  ASA class (1--4)               2.5±0.5            2.7±0.5         0.084
  Smoking, n (%)                 9 (64)             7 (58)          0.756
  Systolic BP (mmHg)             159.2±28.9         149.2±21.8      0.437
  Diastolic BP (mmHg)            83.1±11.5          84.5±11.4       0.574
  Intraocular pressure (mmHg)    15.0±2.9           14.5±3.4        0.769
  Pseudophakic (IOL), n (%)      4 (29)             6 (50)          0.263

**Notes:** Data presented as mean ± SD or absolute number and proportion. For two-group comparisons, qualitative data were analyzed by two-factor *χ*^2^ test and continuous variables by nonparametric Mann--Whitney *U*-test.

**Abbreviations:** ASA, American Society of Anesthesiologists; BMI, body mass index; BP, blood pressure; IOL, intraocular lens; SD, standard deviation.

###### 

Concomitant medication of the study patients

  Medication                                                                 Nonstatin (n=14)   Statin (n=12)   *P*-value
  -------------------------------------------------------------------------- ------------------ --------------- -----------
  Hypercholesterolemia                                                                                          
   Fibrate                                                                   1                  0               0.345
   Statin (simvastatin:atorvastatin)                                         0                  12 (9:3)        
  Diabetes                                                                                                      
   Oral only:insulin only:combination                                        3 (1:0:2)          2 (2:0:0)       0.759
  Hypertension                                                                                                  
   ACE:AT2                                                                   3                  4               0.495
   β-Blocker                                                                 5                  6               0.462
   Calcium channel blocker (vascular:cardioselective)                        3                  2               0.759
   Diuretic                                                                  2                  3               0.490
  Circulation                                                                                                   
   Anticoagulation                                                           0                  1               0.271
   Antithrombotic                                                            6                  6               0.716
   Inotropic                                                                 1                  0               0.345
   Nitrate                                                                   2                  2               0.867
  Central nervous system                                                                                        
   Antidepressive                                                            0                  3               0.047
   Benzodiazepine                                                            0                  1               0.271
   Dementia                                                                  1                  0               0.345
   Nonbenzodiazepine hypnotic                                                0                  1               0.271
  Gastrointestinal tract                                                                                        
   Proton pump inhibitor                                                     2                  2               0.867
  Other hormones and vitamins                                                                                   
   BPH                                                                       1                  1               0.910
   Hormonal substitution                                                     3                  2               0.759
   Thyroxin                                                                  1                  2               0.449
   Vitamins and micronutrients[\*](#tfn4-opth-10-921){ref-type="table-fn"}   2                  3               0.490
  Immunomodulation                                                                                              
   Antihistamines                                                            3                  1               0.356
   Glucocorticoid                                                            1                  0               0.345
   Glucocorticoid inhalated                                                  2                  5               0.117
   NSAIDs                                                                    0                  1               0.271
  Infection                                                                                                     
   Antibiotic                                                                1                  0               0.345
  Topical medication                                                                                            
   Allergy                                                                   1                  0               0.345
   Glaucoma                                                                  0                  1               0.271

**Notes:** Data presented as N-value of concomitant preoperative medication of 14 eyes of 14 nonstatin and 12 eyes of eleven statin-treated patients. For two-group comparisons, qualitative data were analyzed by two-factor *χ*^2^ test.

Vitamins and micronutrients counted by prescription. *P*≤0.05 shows a statistically significant result between the groups.

**Abbreviations:** ACE, angiotensin converting enzyme inhibitor; AT2, angiotensin II receptor antagonist; BPH, benign prostatic hyperplasia; NSAIDs, nonsteroidal anti-inflammatory drugs.

###### 

Intravitreal protein concentrations in nonstatin- and statin-treated iERM patients

                  Nonstatin (n=14)   Statin (n=12)   *P*-value
  --------------- ------------------ --------------- -----------
  Total protein   3.3±2.3            4.1±1.3         0.095
  ANGPT-1         27.8±39.1          12.3±6.1        0.145
  ANGPT-2         82.9±108.5         31.8±22.0       0.176
  EPO             82.9±119.5         10.8±4.9        0.003
  MMP-2           1,710.0±1,185.7    854.1±496.8     0.072
  MMP-9           36.7±47.7          43.8±77.5       1.000
  TGF-β1          15.8±16.3          2.3±4.7         0.035
  VEGF            236.6±491.6        5.5±9.9         0.006

**Notes:** The intravitreal concentrations (ANGPT-1 and -2, VEGF, TGF-β1 \[pg/mL\]; EPO \[mIU/mL\]; or MMP-2 and -9 \[AU/mL\]) in eyes with iERM are given in relation to total protein concentration (mg/mL) in the vitreous sample. Data presented as mean ± SEM. For two-group comparisons, a nonparametric Mann--Whitney *U*-test was used. *P*≤0.05 shows a statistically significant result between the groups.

**Abbreviations:** ANGPT, angiopoietin; EPO, erythropoietin; iERM, idiopathic epiretinal membrane; MMP, matrix metalloproteinase; SEM, standard error of mean; TGF-β1, transforming growth factor-β1; VEGF, vascular endothelial growth factor.

###### 

One-month mean BCVA and 12-month revitrectomy of the study eyes

                            Nonstatin (n=14)   Statin (n=12)   *P*-value
  ------------------------- ------------------ --------------- -----------
  BCVA (pre)                0.76±0.43          0.63±0.17       0.527
  BCVA (1-month)            0.61±0.32          0.37±0.16       0.053
  BCVA gain                 0.16±0.38          0.27±0.20       0.118
  Revitrectomy (12-month)   4                  1               0.219

**Notes:** Data presented as mean ± SD or as number of eyes of observed events in the two groups. For two-group comparisons, continuous variables were analyzed by nonparametric Mann--Whitney *U*-test and hazard of revitrectomy was analyzed using log-rank test. BCVA are given as LogMAR units.

**Abbreviations:** BCVA, best-corrected visual acuity; LogMAR, logarithm of the minimum angle of resolution; SD, standard deviation.
